While you’re here… help us stay here.

Are you enjoying open access to policy and research published by a broad range of organisations? Please donate today so that we can continue to provide this service.


A double dose of inequality: pharma companies and the COVID-19 vaccines crisis

COVID-19 Corporate social responsibility Immunisation Disease management Infectious diseases Pharmaceuticals

The rapid development of effective COVID-19 vaccines in 2020 gave hope to the world in the darkest days of the deadly pandemic. However, the vaccine roll-out has been massively skewed towards wealthy nations. While rich states have hoarded vaccines, companies have also played a decisive role in restricting fair access to a life-saving health product.

This report focuses on six leading vaccine developers, AstraZeneca, BioNTech, Johnson & Johnson, Moderna, Novavax and Pfizer, assessing each company’s human rights policy, pricing structure, records on intellectual property, knowledge and technology sharing, allocation of available vaccine doses and transparency.

Related Information

Money calls the shots https://apo.org.au/node/316441

Publication Details
License type:
Access Rights Type: